BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burmeister BH, Denham JW, O'Brien M, Jamieson GG, Gill PG, Devitt P, Yeoh E, Hamilton CS, Ackland SP, Lamb DS. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. Int J Radiat Oncol Biol Phys. 1995;32:997-1006. [PMID: 7607974 DOI: 10.1016/0360-3016(94)00449-u] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Sun L, Zhao F, Zeng Y, Yi C. Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis. Med Sci Monit 2017;23:889-910. [PMID: 28214903 DOI: 10.12659/msm.903328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
2 Bae SH, Park W, Choi DH, Nam H, Kang WK, Park YS, Park JO, Chun HK, Lee WY, Yun SH. Palliative radiotherapy in patients with a symptomatic pelvic mass of metastatic colorectal cancer. Radiat Oncol. 2011;6:52. [PMID: 21600018 DOI: 10.1186/1748-717x-6-52] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
3 Wolf M, Zehentmayr F, Niyazi M, Ganswindt U, Haimerl W, Schmidt M, Hölzel D, Belka C. Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol. 2010;186:374-381. [PMID: 20582393 DOI: 10.1007/s00066-010-2137-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
4 Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, Ajani JA, Crane CH, Krishnan S. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol 2008;47:421-7. [PMID: 17899453 DOI: 10.1080/02841860701621233] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
5 Burmeister BH, Walpole ET, D'Arcy N, Burmeister EA, Cox S, Thomson DB, Harvey JA, Smithers BM. A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer. Invest New Drugs 2009;27:275-9. [PMID: 18841327 DOI: 10.1007/s10637-008-9178-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
6 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
7 Jingu K, Nemoto K, Matsushita H, Takahashi C, Ogawa Y, Sugawara T, Nakata E, Takai Y, Yamada S. Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. BMC Cancer. 2006;6:50. [PMID: 16515704 DOI: 10.1186/1471-2407-6-50] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
8 Kaneko K, Ito H, Konishi K, Kurahashi T, Ito T, Katagiri A, Yamamoto T, Kitahara T, Mizutani Y, Ohtsu A. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer. 2003;88:18-24. [PMID: 12556953 DOI: 10.1038/sj.bjc.6600684] [Cited by in Crossref: 65] [Cited by in F6Publishing: 75] [Article Influence: 3.4] [Reference Citation Analysis]
9 Fritz P, Wannenmacher M. Radiotherapy in the multimodal treatment of esophageal carcinoma. Strahlenther Onkol. 1997;173:295-308. [PMID: 9235637 DOI: 10.1007/BF03038912] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
10 Wong WW, Schild SE, Martenson JA. Role of Radiation Therapy and Fluoropyrimidines in the Treatment of Gastrointestinal Malignancies. Cancer Control 1996;3:319-28. [PMID: 10765223 DOI: 10.1177/107327489600300403] [Reference Citation Analysis]